Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

calcipotriene 0.005% and betamethasone dipropionate 0.064%

×

Overview

What is CALCIPOTRIENE 0.005% AND BETAMETHASONE DIPROPIONATE 0.064%?

Calcipotriene and betamethasone dipropionate ointment contains calcipotriene and betamethasone dipropionate. It is intended for topical use only.

Calcipotriene is a synthetic vitamin D analog.

Chemically, calcipotriene is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19), 22-tetraene-1(alpha),3(beta),24-triol, with the empirical formula CHO, a molecular weight of 412.3, and the following structural formula:

:

Calcipotriene is a white to almost white crystalline compound.

Betamethasone dipropionate is a synthetic corticosteroid.  

Betamethasone dipropionate has the chemical name 9-fluoro-11(beta),17,21-trihydroxy-16(beta)-methylpregna-1,4-diene-3,20-dione17,21-dipropionate, with the empirical formula CHFO, a molecular weight of 504.6, and the following structural formula:

Betamethasone dipropionate is a white to almost white odorless powder.

Each gram of calcipotriene and betamethasone dipropionate ointment contains 50 mcg of calcipotriene and 0.643 mg of betamethasone dipropionate (equivalent to 0.5 mg of betamethasone) in  off-white to yellow paraffin ointment base of caprylic/capric triglycerides, diazolidinyl urea, dl-alpha tocopherol and white petrolatum.



What does CALCIPOTRIENE 0.005% AND BETAMETHASONE DIPROPIONATE 0.064% look like?



What are the available doses of CALCIPOTRIENE 0.005% AND BETAMETHASONE DIPROPIONATE 0.064%?

Ointment, 0.005%/0.064%

Each gram of calcipotriene and betamethasone dipropionate ointment contains 50 mcg of calcipotriene and 0.643 mg of betamethasone dipropionate (equivalent to 0.5 mg of betamethasone). ( )

What should I talk to my health care provider before I take CALCIPOTRIENE 0.005% AND BETAMETHASONE DIPROPIONATE 0.064%?

How should I use CALCIPOTRIENE 0.005% AND BETAMETHASONE DIPROPIONATE 0.064%?

Calcipotriene and betamethasone dipropionate ointment is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.

Pediatric use information for patients ages 12 years and above is approved for LEO Pharma A/S’s Taclonex® (calcipotriene and betamethasone dipropionate) Ointment. However, due to LEO Pharma A/S’s marketing exclusivity rights, this drug product is not labeled with that information.

Apply an adequate layer of calcipotriene and betamethasone dipropionate ointment to the affected area(s) once daily for up to 4 weeks. Calcipotriene and betamethasone dipropionate ointment should be rubbed in gently and completely. Patients should wash their hands after applying calcipotriene and betamethasone dipropionate ointment.  Therapy should be discontinued when control is achieved.

Patients 18 years and older should not use more than 100 g per week. Treatment of more than 30% body surface area is not recommended.

Calcipotriene and betamethasone dipropionate ointment should not be used with occlusive dressings unless directed by a physician. Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site. Calcipotriene and betamethasone dipropionate ointment is not for oral, ophthalmic, or intravaginal use.

Pediatric use information for patients ages 12 years and above is approved for LEO Pharma A/S’s Taclonex® (calcipotriene and betamethasone dipropionate) Ointment. However, due to LEO Pharma A/S’s marketing exclusivity rights, this drug product is not labeled with that information.


What interacts with CALCIPOTRIENE 0.005% AND BETAMETHASONE DIPROPIONATE 0.064%?

Sorry No Records found


What are the warnings of CALCIPOTRIENE 0.005% AND BETAMETHASONE DIPROPIONATE 0.064%?

Sorry No Records found


What are the precautions of CALCIPOTRIENE 0.005% AND BETAMETHASONE DIPROPIONATE 0.064%?

Sorry No Records found


What are the side effects of CALCIPOTRIENE 0.005% AND BETAMETHASONE DIPROPIONATE 0.064%?

Sorry No records found


What should I look out for while using CALCIPOTRIENE 0.005% AND BETAMETHASONE DIPROPIONATE 0.064%?

None.


What might happen if I take too much CALCIPOTRIENE 0.005% AND BETAMETHASONE DIPROPIONATE 0.064%?

Sorry No Records found


How should I store and handle CALCIPOTRIENE 0.005% AND BETAMETHASONE DIPROPIONATE 0.064%?

Store at 25°C (77°F) with excursions permitted between 15–30°C (59–86°F) [see USP Controlled Room Temperature].All regulations concerning handling of pressure vessels must be followed.Protect the cylinders from shocks, falls, oxidizing and flammable materials, moisture, and sources of heat or ignition.Store at 25°C (77°F) with excursions permitted between 15–30°C (59–86°F) [see USP Controlled Room Temperature].All regulations concerning handling of pressure vessels must be followed.Protect the cylinders from shocks, falls, oxidizing and flammable materials, moisture, and sources of heat or ignition.Store at 25°C (77°F) with excursions permitted between 15–30°C (59–86°F) [see USP Controlled Room Temperature].All regulations concerning handling of pressure vessels must be followed.Protect the cylinders from shocks, falls, oxidizing and flammable materials, moisture, and sources of heat or ignition.Intravenous sotalol is supplied in 10 mL vials, each containing 150 mg of sotalol hydrochloride (15 mg/mL). NDC 69724-112-10carton containing one, 10 mL vialStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from freezing and light.Manufactured by:  Galway, IrelandManufactured for: Chicago, IL 60606 U.S.A.Intravenous sotalol is supplied in 10 mL vials, each containing 150 mg of sotalol hydrochloride (15 mg/mL). NDC 69724-112-10carton containing one, 10 mL vialStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from freezing and light.Manufactured by:  Galway, IrelandManufactured for: Chicago, IL 60606 U.S.A.Intravenous sotalol is supplied in 10 mL vials, each containing 150 mg of sotalol hydrochloride (15 mg/mL). NDC 69724-112-10carton containing one, 10 mL vialStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from freezing and light.Manufactured by:  Galway, IrelandManufactured for: Chicago, IL 60606 U.S.A.Intravenous sotalol is supplied in 10 mL vials, each containing 150 mg of sotalol hydrochloride (15 mg/mL). NDC 69724-112-10carton containing one, 10 mL vialStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from freezing and light.Manufactured by:  Galway, IrelandManufactured for: Chicago, IL 60606 U.S.A.Intravenous sotalol is supplied in 10 mL vials, each containing 150 mg of sotalol hydrochloride (15 mg/mL). NDC 69724-112-10carton containing one, 10 mL vialStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from freezing and light.Manufactured by:  Galway, IrelandManufactured for: Chicago, IL 60606 U.S.A.Intravenous sotalol is supplied in 10 mL vials, each containing 150 mg of sotalol hydrochloride (15 mg/mL). NDC 69724-112-10carton containing one, 10 mL vialStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from freezing and light.Manufactured by:  Galway, IrelandManufactured for: Chicago, IL 60606 U.S.A.Intravenous sotalol is supplied in 10 mL vials, each containing 150 mg of sotalol hydrochloride (15 mg/mL). NDC 69724-112-10carton containing one, 10 mL vialStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from freezing and light.Manufactured by:  Galway, IrelandManufactured for: Chicago, IL 60606 U.S.A.Intravenous sotalol is supplied in 10 mL vials, each containing 150 mg of sotalol hydrochloride (15 mg/mL). NDC 69724-112-10carton containing one, 10 mL vialStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from freezing and light.Manufactured by:  Galway, IrelandManufactured for: Chicago, IL 60606 U.S.A.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Calcipotriene and betamethasone dipropionate ointment combines the pharmacological effects of calcipotriene as a synthetic vitamin D analogue and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in plaque psoriasis are unknown.

Non-Clinical Toxicology
None.

Hypercalcemia and hypercalciuria have been observed with use of calcipotriene and betamethasone dipropionate ointment. If hypercalcemia or hypercalciuria develops, treatment should be discontinued until parameters of calcium metabolism have normalized. In the trials that included assessment of the effects of calcipotriene and betamethasone dipropionate ointment on calcium metabolism, such testing was done after 4 weeks of treatment. The effects of calcipotriene and betamethasone dipropionate ointment on calcium metabolism following treatment durations of longer than 4 weeks have not been evaluated.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).